Miniatura

Fitxers

jcm-10-02914-v3.pdf (1.13 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-06-29

Llicència de publicació

cc by (c) Albshesh, Ahmad et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179326

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm10132914

Resum

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

Matèries

Malaltia de Crohn, Malalties inflamatòries intestinals

Matèries (anglès)

Inflammatory bowel diseases, Crohn's disease

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ALBSHESH, Ahmad, TAYLOR, Joshua, SAVARINO, Edoardo v., TRUYENS, Marie, ARMUZZI, Alessandro, RIBALDONE, Davide g., SHITRIT, Ariella bar-gil, FIBELMAN, Morine, MOLANDER, Pauliina, LIEFFERINCKX, Claire, NANCEY, Stephane, KORANI, Mohamed, RUTKA, Mariann, BARREIRO DE ACOSTA, Manuel, DOMISLOVIC, Viktor, SURIS, Gerard, ERIKSSON, Carl, ALVES, Catarina, MPITOULI, Afroditi, DI JIANG, Caroline, TEPEŠ, Katja, COLETTA, Marina, FOTEINOGIANNOPOULOU, Kalliopi, GISBERT, Javier p., AMIR-BARAK, Hadar, ATTAUABI, Mohamed, SEIDELIN, Jakob, AFIF, Waqqas, MARINELLI, Carla, LOBATÓN, Triana, PUGLIESE, Daniela, MAHARSHAK, Nitsan, CREMER, Anneline, LIMDI, Jimmy k., MOLNÁR, Tamás, OTERO ALVARIN, Borja, KRZNARIC, Zeljko, MAGRO, Fernando, KARMIRIS, Konstantinos, RAINE, Tim, DROBNE, David, KOUTROUBAKIS, Ioannis, CHAPARRO, Maria, YANAI, Henit, BURISCH, Johan, KOPYLOV, Uri. Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study. _Journal of Clinical Medicine_. 2021. Vol. 10, núm. 13, pàgs. 2914. [consulta: 9 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/179326]

Exportar metadades

JSON - METS

Compartir registre